Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha

Related Keywords

Belgium ,Belgian ,Miconazole Domiphen ,Jean Luc Vandebroek ,Stijn Van Rompay ,Hyloris Pharmaceuticals ,Purna Pharmaceuticals ,Linkedin ,Hyloris Pharmaceuticals Sa Euronext Brussels ,Purna Female Healthcare Announce Positive Results ,Acute Vulvovaginal Candidiasis ,Domiphen Bromide ,Euronext Brussels ,Miconazole Domiphen Bromide ,Van Rompay ,Chief Executive Officer ,Female Healthcare ,Luc Vandebroek ,Lancet Infectious Diseases ,Clinical Infectious Diseases ,Expert Opinion ,Vulvovaginal Candidiasis ,Clinical Outcome ,The Company ,Liège ,Qurna ,Pharmaceuticals ,Efficacy ,